Advancing Defined Microbial Consortia Mechanisms in STARFISH‑UC Development to Improve Ulcerative Colitis Clinical Outcomes

• Presenting early clinical data from STARFISH UC trials to validate safety, efficacy signals, and differentiation versus FMT and single-strain therapies
• Demonstrating mechanism of action of rationally designed microbial consortia to drive targeted anti-inflammatory pathways and improve engraftment consistency
• Leveraging translational biomarkers and patient stratification strategies to optimize responder identification and enhance clinical trial design success rates

Speakers:

Katja Conrath

Chief Scientific Officer

MRM Health